Detalhe da pesquisa
1.
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.
Nature
; 629(8011): 443-449, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38658754
2.
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Nature
; 543(7647): 733-737, 2017 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28329763
3.
Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.
Proc Natl Acad Sci U S A
; 114(12): 3151-3156, 2017 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28265066
4.
M2 isoform of pyruvate kinase is dispensable for tumor maintenance and growth.
Proc Natl Acad Sci U S A
; 110(2): 489-94, 2013 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23267074
5.
Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.
Proc Natl Acad Sci U S A
; 109(20): E1267-76, 2012 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22529373
6.
Acentrosomal spindle organization renders cancer cells dependent on the kinesin HSET.
J Cell Sci
; 125(Pt 22): 5391-402, 2012 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22946058
7.
Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Nat Cancer
; 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38565920
8.
The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences.
Chembiochem
; 14(10): 1218-25, 2013 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23780915
9.
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Cancer Cell
; 5(3): 221-30, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15050914
10.
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.
Cancer Cell
; 5(3): 231-9, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15050915
11.
2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.
Bioorg Med Chem Lett
; 20(5): 1724-7, 2010 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20138510
12.
Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models.
Comput Struct Biotechnol J
; 18: 323-331, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32099592
13.
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.
Oncotarget
; 11(11): 956-968, 2020 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32215184
14.
Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Clin Cancer Res
; 25(10): 3164-3175, 2019 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30674502
15.
A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.
PLoS One
; 14(10): e0221635, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31600213
16.
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
Mol Cancer Ther
; 18(12): 2194-2206, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31409633
17.
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Br J Haematol
; 141(4): 470-82, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18341634
18.
Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
Clin Cancer Res
; 13(4): 1322-30, 2007 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17317844
19.
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
Cancer Res
; 66(3): 1500-8, 2006 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16452206
20.
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.
Cancer Res
; 78(21): 6257-6267, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30135191